Evidence-based Mobile Medical Applications in Diabetes

Andjela Drincic; Priya Prahalad; Deborah Greenwood; David C Klonoff

doi:10.1016/j.ecl.2016.06.001

Evidence-based Mobile Medical Applications in Diabetes

Endocrinol Metab Clin North Am. 2016 Dec;45(4):943-965. doi: 10.1016/j.ecl.2016.06.001. Epub 2016 Oct 8.

Authors

Andjela Drincic¹, Priya Prahalad², Deborah Greenwood³, David C Klonoff⁴

Affiliations

¹ Nebraska Medicine, Diabetes Center, 4400 Emile Street, Omaha, NE 68198, USA. Electronic address: andjela.drincic@unmc.edu.
² Division of Endocrinology and Diabetes, Pediatrics, Stanford University, 300 Pasteur Drive, Room G313, MC 5208, Stanford, CA 94305, USA.
³ Sutter Health Integrated Diabetes Education Network, Quality and Clinical Effectiveness Team, Office of Patient Experience, Sutter Health, 2200 River Plaza Drive, Sacramento, CA 95833, USA.
⁴ Diabetes Research Institute, Mills-Peninsula Health Services, 100 South San Mateo Drive, Room 5147, San Mateo, CA 94401, USA.

Abstract

This article reviews mobile medical applications that are commercially available in the United States or European Union (EU) and are (1) associated with published data of clinical outcomes in the peer-reviewed literature during the past 5 years, (2) cleared by the US Food and Drug Administration (FDA) in the United States, or (3) a recipient of a CE (Conformité Européenne) mark by the EU. Many of these applications have been shown to positively affect outcomes in the short term, but long-term studies are needed. Until more data are available, consumers and professionals can consider guidance based on FDA/CE status.

Keywords: Applications; Diabetes; Glucose; Medical; Mobile; Telemedicine; mHealth.

Publication types

Review

MeSH terms

Diabetes Mellitus / therapy*
European Union
Evidence-Based Medicine
Humans
Mobile Applications*
United States

Grants and funding

T32 DK007161/DK/NIDDK NIH HHS/United States